AMA chief urges regulators to keep pace with emerging AI-driven medical care

The American Medical Association’s chief executive highlighted the rapid progress toward autonomous, AI‑based medical treatments and warned that regulatory frameworks are lagging behind. He emphasized the need for clear guidance to ensure safety and efficacy as these technologies move closer to clinical use.

In August, the U.S. Food and Drug Administration issued a discussion paper outlining potential approaches for overseeing AI‑driven care. The paper seeks input from stakeholders on how best to evaluate algorithms that continuously learn and adapt.

The AMA leader called for collaborative efforts among industry, clinicians, and regulators to develop standards that protect patients while fostering innovation. He noted that timely regulatory action will be critical to realizing the benefits of AI in healthcare.

The conversation reflects broader industry concerns that policy must evolve quickly enough to match the speed of technological advancement, ensuring that new AI tools can be safely integrated into practice.